Systematic review / meta-analysis / 2012
Evidence is insufficient to recommend the generalized use of collagen hydrolysate in clinical practice for osteoarthritis.
A systematic review identified 8 studies evaluating collagen derivatives (six on collagen hydrolysate [CH], two on gelatine, and one on undenatured collagen [UC]) in osteoarthritis patients. The pooled mean difference across three studies for WOMAC pain reduction comparing CH with placebo was -0.49 (95% CI -1.10 to 0.12), with no significant differences for disability. Gelatine was superior to placebo and alternative therapies for pain, whereas UC showed no significant differences compared to glucosamine plus chondroitin. Adverse events were mostly mild to moderate gastrointestinal complaints, and overall evidence quality was moderate to very low.
- Study type
- Systematic review and meta-analysis of RCTs and quasi-RCTs
- Who was studied
- Patients with osteoarthritis across 8 identified studies
- What was measured
- Pain reduction (WOMAC, VAS), disability, and adverse events
THE PAPER
Symptomatic and chondroprotective treatment with collagen derivatives in osteoarthritis: a systematic review.
Van Vijven JP, Luijsterburg PA, Verhagen AP, van Osch GJ, Kloppenburg M, Bierma-Zeinstra SM. Osteoarthritis Cartilage, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.